Anecdotal case reports of successful treatment of patients with refractory cutaneous sarcoidosis using JAK inhibitors (301–303), and immunological evidence of JAK-STAT pathway activation in patients with sarcoidosis (186, 304) has raised interest in the possible use of JAK inhibitors in patients with sarcoidosis (18). Here, SOAT1 is linked to sarcoidosis.